-
-
-
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
- 2024.12.4 ｜ 抄読会論文
- 抄読会要旨 猿渡功一...
-
-
-
-
育成賞を受賞しました！
- 2024.10.18 ｜ お知らせ
- 先日開催されました、第93回日本呼吸器学会九州支部秋季学術講演会にて 「免疫化学療法後の増悪に対して...
-
-
-
-
Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study
- 2024.07.10 ｜ 抄読会論文
- 抄読会要旨 今村光佑...
-
-
-
-
eClinical Medicine. 2024 Mar 22:70:102536. doi:10.1016/j.eclinm.2024.102536Title : Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
- 2024.06.7 ｜ 抄読会論文
- 抄読会要旨 猪山慎治...
-
-
-
-
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462.
- 2024.05.16 ｜ 抄読会論文
- 抄読会要旨 猿渡 功一...
-
-
-
-
5/11sat.16:30～医局説明会を開催します☆
- 2024.03.29 ｜ お知らせ
- 医局説明会2024PDF 令和6年度医局説明会を5月11日土曜日16時30分から開催し...
-
-
-
-
呼吸器内科塾2024 開催のお知らせ 参加は無料！ 当日参加も可能
- 2024.04.2 ｜ お知らせ
- 呼吸器内科塾 2024 ...
-
-
-
-
Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy
- 2024.02.19 ｜ 抄読会論文
- 抄読会要旨 岡林比呂子...
-
-
-
-
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
- 2023.11.1 ｜ 抄読会論文
- 抄読会要旨 今村光佑...
-
-
-
-
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
- 2023.10.27 ｜ 抄読会論文
- 抄読会要旨 猪山慎治...
-
